Abstract 1876P
Background
Societal beliefs about cancer can impact how patients perceive their disease generating cancer stigma (CS) with risk of emotional distress especially in Arab countries where cancer remains a taboo. This study aimed to evaluate aspects of CS according to Tunisian cancer patients, explore risk factors and describe the impact on mental health.
Methods
The study was a cross-sectional questionnaire-based study, conducted between February and April 2023, including 100 patients treated for cancer regardless of gender, type or stage. We developed the questionnaire by adapting items from the “Cancer stigma scale” using questions grouped in three domains: impossibility of recovery, stereotypes of cancer patients and experience of social discrimination. Depression and anxiety were evaluated by using the “Hospital Anxiety and Depression Scale”.
Results
Median age was 50 years old, 75% of patients were women. On average, patients were surveyed 20.48 months after diagnosis. Patients reported at least one form of CS in 57% of cases. They believed in the impossibility of recovery after cancer experience in 47% of cases. Forty percent of patients held stereotypical views of themselves: 48% endorsed that cancer patients would have a difficult time having sexual intimacy which was the item with the highest mean (2.45) among all questions. Thirty four percent of patients reported social discrimination on grounds of cancer: by family/spouse in 31%, at the workplace in 15% and by friends/neighbors in 13% of cases. Cancer stigma was significantly more perceived by patients with low socioeconomic status (OR= 3.74 [1.42-9.82]), living in rural areas (OR=26 [3.38-205] and with advanced stage disease (OR=4.2 [1.67-10.5]). Forty percent of patients reported significant depressive symptoms and 47% significant anxiety symptoms. Patients who experienced CS were 4.27 times more likely to have depression (p <0.001) and 3.57 times more probably to be anxious (p <0.001) than patients with positive attitudes.
Conclusions
Despite increased awareness, cancer patients had high levels of CS with negative impact on mental health. These results ring the alarm bell to change societal beliefs and to help patients perceive “better” their disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05